ATTO logo

Attovia Therapeutics, Inc.

ATTO
Healthcare|Biotechnology|US
$15.27
+0.27 (+1.80%)
DCF Value
$0.98
Tangible Book / Share
$2.47
Cash / Share
$2.52

Financials

Financial Snapshot

Market Cap
$697.1M
Enterprise Value
$668.6M
Revenue (TTM)
$450.0K
Net Income (TTM)
-$68.9M
Cash & Investments
$115.1M
Net Cash
$110.8M
Free Cash Flow (TTM)
-$63.9M
Operating CF (TTM)
-$61.6M
Debt/Equity
0.04

Cash Runway & Burn Rate

Cash on Hand
$115.1M
Quarterly Burn
$15.4M
Monthly Burn
$5.1M
Est. Runway
~7.5 quarters
MetricTrend20242025TTM
Cash & Investments
$69.3M$152.3M$115.1M
Operating Cash Flow
-$35.0M-$59.2M-$61.6M
Free Cash Flow
-$36.8M-$61.5M-$63.9M
Capital Expenditure
-$1.8M-$2.3M-$2.2M
Financing Cash Flow
$82.7M$142.0M$140.2M

R&D Spending

R&D (TTM)
$61.1M
R&D Intensity
13585.8%
R&D Growth vs Prior
+12.9%
MetricTrend20242025TTM
Revenue
$0.00$1.4M$450.0K
R&D Expense
$33.9M$54.2M$61.1M
R&D % of Revenue
—4011.3%13585.8%
SG&A
$7.4M$13.6M$13.2M

Income Statement

MetricTrend20242025TTM
Revenue
$0.00$1.4M$450.0K
Cost of Revenue
$313.0K$804.0K$631.0K
Gross Profit
-$313.0K$546.0K-$181.0K
R&D
$33.9M$54.2M$61.1M
SG&A
$7.4M$13.6M$13.2M
Operating Income
-$41.6M-$67.2M-$74.5M
Interest Expense
$0.00$0.00$0.00
Pretax Income
-$39.8M-$60.6M-$68.9M
Net Income
-$39.8M-$60.6M-$68.9M
EPS (Diluted)
-1.05-1.42-1.89
EBITDA
-$41.2M-$66.4M-$73.6M
Shares Out. (M)
43.0343.0345.65

Balance Sheet

MetricTrend20242025TTM
Cash & Equivalents
$30.6M$40.2M$32.8M
Short-Term Investments
$38.7M$112.1M$82.3M
Total Current Assets
$72.5M$156.3M$118.4M
Total Assets
$76.7M$165.9M$128.3M
Total Current Liabilities
$7.7M$11.0M$12.6M
Long-Term Debt
$0.00$0.00$0.00
Total Liabilities
$14.6M$15.1M$15.6M
Stockholders' Equity
$62.1M$150.8M$112.8M
Retained Earnings
-$50.4M-$111.0M-$150.4M

Cash Flow Statement

MetricTrend20242025TTM
Operating Cash Flow
-$35.0M-$59.2M-$61.6M
Capital Expenditure
-$1.8M-$2.3M-$2.2M
Free Cash Flow
-$36.8M-$61.5M-$63.9M
Investing Cash Flow
-$39.8M-$73.5M-$74.1M
Financing Cash Flow
$82.7M$142.0M$140.2M
Issuance of Stock
$82.9M$142.0M$140.2M
Repurchase of Stock
$0.00$0.00$0.00
Net Debt Issuance
-$171.0K$0.00$0.00
Stock Based Comp.
$0.00$0.00$563.0K
Net Change in Cash
$30.6M$9.6M-$53.8M

Dilution Tracker

Shares Outstanding
46M
5-Year Share Growth
+0.0%
Stock Issuance (TTM)
$140.2M
MetricTrend20242025TTM
Shares Out. (M)
43.0343.0345.65
Change vs Prior %
—0.0%6.1%
Stock Issuance
$82.9M$142.0M$140.2M
Stock Repurchase
$0.00$0.00$0.00
Stock Based Comp.
$0.00$0.00$563.0K

Margins & Profitability

MetricTrend20242025TTM
Gross Margin %
—40.4%-40.2%
Operating Margin %
—-4974.7%-16551.6%
Net Margin %
—-4490.9%-15318.4%
EBITDA Margin %
—-4915.2%-16365.3%
FCF Margin %
—-4556.4%-14194.7%
ROE %
-64.1%-40.2%-32.1%
ROA %
-51.9%-36.5%-30.7%
ROIC %
-60.2%-42.8%-35.5%
R&D / Revenue %
—4011.3%13585.8%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend20242025
Revenue
0.0%0.0%
Gross Profit
0.0%274.4%
Operating Income
0.0%-61.6%
Net Income
0.0%-52.3%
EPS (Diluted)
0.0%-35.2%
Operating Cash Flow
0.0%-69.0%
Free Cash Flow
0.0%-67.1%
R&D Expense
0.0%59.9%
SG&A Expense
0.0%83.7%
Total Assets
0.0%116.2%
Book Value / Share
0.0%142.7%
Debt
0.0%0.0%
Diluted Shares
0.0%0.0%

Valuation

P/E (TTM)At Loss
P/S1549.10
P/B6.18
EV/EBITDAAt Loss
EV/Revenue1485.76
P/FCFAt Loss

Intrinsic Value Models (per share)

DCF Value
$0.98
Tangible Book / Share
$2.47
Net Current Assets / Share
$2.25
Graham Net-Net
$2.18
Cash / Share
$2.52
MetricTrend20242025TTM
P/E Ratio
-20.86-15.42-16.42
P/S Ratio
0.00698.031549.10
P/B Ratio
15.176.256.18
EV/EBITDA
-22.11-13.67-16.20
EV/Revenue
0.00672.151485.76

Analyst Estimates & Quality

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$450.0K$1.4M$1.4M
Net Income-$178.8M-$104.8M-$103.9M
EPS$-4.06$-2.38$-2.44
# Analysts (EPS)113